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Abstract
Introduction: Extracorporeal membrane oxygenation (ECMO) after cardiac operations (postcardiotomy) is commonly
used for the treatment of acute heart failure refractory to drug treatment. Bleeding and thromboembolic events are the
most common complications of postcardiotomy ECMO. The present study is a retrospective comparison of the
conventional heparin-based anticoagulation protocol with a bivalirudin-based, heparin-free protocol. Endpoints of this
study are blood loss, allogeneic blood product use, and costs during the ECMO procedure.
Methods: A retrospective study was undertaken in the setting of cardiac surgery, anesthesia, and intensive care
departments of a university research hospital. Twenty-one patients (12 adults and nine children) who underwent
postcardiotomy ECMO from 2008 through 2011 were retrospectively analyzed. The first consecutive eight patients
were treated with heparin-based anticoagulation (H-group) and the next 13 consecutive patients with bivalirudin-
based anticoagulation (B-group). The following parameters were analyzed: standard coagulation profile,
thromboelastographic parameters, blood loss, allogeneic blood products use, thromboembolic complications, and
costs during the ECMO treatment.
Results: Patients in the B-group had significantly longer activated clotting times, activated partial thromboplastin
times, and reaction times at thromboelastography. The platelet count and antithrombin activity were not
significantly different, but in the H-group a significantly higher amount of platelet concentrates, fresh frozen
plasma, and purified antithrombin were administered. Blood loss was significantly lower in the B-group, and the
daily cost of ECMO was significantly lower in pediatric patients treated with bivalirudin. Thromboembolic
complications did not differ between groups.
Conclusions: Bivalirudin as the sole anticoagulant can be safely used for postcardiotomy ECMO, with a better
coagulation profile, less bleeding, and allogeneic transfusions. No safety issues were raised by this study, and costs
are reduced in bivalirudin-treated patients.
Introduction
Extracorporeal membrane oxygenation (ECMO) is
widely used for the circulatory and/or respiratory sup-
port of adult and pediatric patients in a number of clini-
cal situations, including end-stage cardiac failure, acute
heart failure, acute respiratory failure, and cardiopul-
monary resuscitation [1-5].
Postcardiotomy ECMO for the treatment of acute
heart failure following cardiac operations presents speci-
fic challenges in anticoagulation management. When the
ECMO system is implanted at the end of the heart
operation, or in the first postoperative hours, the dele-
terious effects of cardiopulmonary bypass on the coagu-
lation system are still active, and both massive bleeding
and thromboembolic complications are common events
[6,7]. In a recent series of 108 cardiac surgery patients
requiring ECMO for postcardiotomy acute heart failure, * Correspondence: cardioanestesia@virgilio.it
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quent causes of death [8].
The standard anticoagulation treatment for ECMO
patients is based on a continuous infusion of unfractio-
nated heparin to reach and maintain an activated clot-
ting time (ACT) of 160 to 200 seconds. Heparin
anticoagulation chronically consumes antithrombin
(AT), activates platelets, and may result in nonimmune-
mediated thrombocytopenia as well as in heparin-
induced thrombocytopenia (HIT). HIT in ECMO
patients is quite a common feature, with reported rates
of 10 to 15% [9,10], and is of course a catastrophic com-
plication of this procedure.
Starting in June 2009, we have been performing post-
cardiotomy ECMO in cardiac surgery patients (new-
borns, infants, children and adults) with a heparin-free
anticoagulation management, based on bivalirudin as
the sole anticoagulant. The shift from the conventional
heparin-based protocol to the bivalirudin-based protocol
was internally decided by consensus among cardiac sur-
geons and anesthesiologists after two cases of HIT in
ECMO patients that were successfully treated by stop-
ping heparin administration and starting a bivalirudin
infusion. The present study is a retrospective compara-
tive analysis of the conventional heparin-based anticoa-
gulation (from January 2008 through May 2009) versus
the bivalirudin-based anticoagulation (from June 2009
through April 2011) with a specific respect for blood
loss, thromboembolic complications, allogeneic blood
product use, and costs associated with postcardiotomy
ECMO.
Materials and methods
The present study was approved by the local ethics
committee, and the need for informed consent from the
patients was waived. At hospital admission, all patients
gave written approval for the treatment of their data in
an anonymous form for scientific purposes.
Patients
The patient population comprises all of the postcardiot-
omy ECMO procedures performed at our institution
from 1 January 2008 through 30 April 2011, for a total
of 21 cases. Eight consecutive cases were treated with
conventional heparin-based anticoagulation (H-group)
and the following 13 consecutive cases with a heparin-
less, bivalirudin-based anticoagulation (B-group). Two
cases where the conventional heparin-based anticoagula-
tion was replaced by bivalirudin anticoagulation were
not included in the patient population.
Extracorporeal membrane oxygenation procedure
The following ECMO circuits have been used during
the study period: for patients < 10 kg body weight, the
circuit was assembled using a Biomedicus BP50 centri-
fugal pump (Medtronic, Minneapolis, MN, USA) and a
Dideco Lilliput 2 ECMO oxygenator (Sorin Group,
Mirandola, Italy) with phosphorylcholine biocompatible
treatment; for patients weighing > 10 kg, different cir-
cuits have been used according to availability - the
centrifugal pumps used were the Biomedicus BP80
(Medtronic), the Stockert Revolution (Sorin Group), or
the Levitronix (Levitronix, Waltham, MA, USA)
equipped with the Dideco EOS ECMO (Sorin Group)
oxygenator with phosphorycholine biocompatible treat-
ment. In the last 6 months a preassembled ECMO sys-
tem (permanent life support; Maquet, Rastatt,
Germany) with a Rotaflow centrifugal pump and a
Quadrox PLS oxygenator with Bioline
® coating
(Maquet, Rastatt, Germany ) was used in adult
patients. Only one patient in the B-group received
treatment with this system.
In all patients there was a direct heart cannulation
with the venous cannula placed in the right atrium, an
additional venous cannula of smaller size in the left
atrium, and the arterial cannula placed in the ascending
aorta. The sternum was mostly left open, covered by an
adhesive plastic membrane, but in some cases it was
closed with the cannulas passed through the thorax and
fixed to the chest wall.
The ECMO was usually performed at full flow, under
normothermic conditions guaranteed by the oxygenator
heat exchanger, a heater-cooler external group, and
external heat-exchanging blankets.
Anticoagulation protocol and transfusion policy
Anticoagulation monitoring during ECMO was obtained
using the ACT, the activated partial thromboplastin
time (aPTT) and kaolin-activated thromboelastography
(Haemoscope, Niles, IL, USA), with target values reflect-
ing the usual clinical practice [11]. The ACT was
repeated every 4 hours and the target value was 160 to
180 seconds. The aPTT was repeated every 12 hours,
with a target value of 50 to 80 seconds; the thromboe-
lastography was repeated every 8 hours, with a target
value for the r time placed at a minimum of 12 and a
maximum of 30 minutes.
The initial anticoagulation protocol was different
depending on the timing of the ECMO implant. In
patients under cardiopulmonary bypass with full heparin
treatment, where the ECMO was implanted due to the
inability to wean the patient from the cardiopulmonary
bypass, the heparin was fully antagonized with prota-
mine after the ECMO implantation. Subsequently, the
patient was observed for bleeding control. No anticoagu-
lants were used until the patient was actively bleeding (>
4 ml/kg/hour). Once the blood loss was contained and
stabilized, the anticoagulation protocol was started and
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previously described.
In patients where the systemic heparin used for the
cardiac operation was already antagonized, and the
ECMO was implanted subsequently to protamine
administration, a bolus dose of heparin (100 IU/kg) was
used for cannulation. Once the ECMO was established,
the heparin was fully antagonized with protamine and
again the patient entered the observation period for
severe bleeding before starting any anticoagulation treat-
ment. In the H-group, patients received a continuous
intravenous infusion of unfractionated heparin at an
initial dose of 5 to 10 IU/kg/hour depending on the
bleeding rate. The dose was subsequently adjusted
according to the ACT, aPTT, and r time values. In the
B-group, patients received a continuous infusion of biva-
lirudin at an initial dose of 0.03 to 0.05 mg/kg/hour
depending on the bleeding rate. The dose was subse-
quently adjusted according to the ACT, aPTT, and r
time values. In patients with a reduced creatinine clear-
ance, the starting dose was halved.
For both groups, the dose of heparin and bivalirudin
was adjusted according to three variables: ACT, r time,
and aPTT. Given the different daily frequency of mea-
surement for these variables, the adjustments were dri-
ven initially by the ACT, and subsequently confirmed
(or readjusted) according to the r time and, finally, to
the aPTT.
Allogeneic blood products were administered accord-
ing to a specific protocol. Packed red cells were trans-
fused for hemoglobin values < 8 to 9 g/dl. Fresh frozen
plasma was used for the treatment of active bleeding
especially in the first postoperative hours. Platelet con-
centrates were used to maintain the platelet count >
80,000 cells/μl in the patient with active bleeding and >
50,000 cells/μl in the stable, nonbleeding patient. Fibri-
nogen was not commercially available in Italy during
the study period and was never used. AT activity was
maintained at > 60% by replenishment with purified AT.
Additional options for treating life-threatening bleed-
ing included the use of recombinant activated factor VII
and, for bivalirudin-treated patients, hemofiltration.
Data collection
Data retrieved from the patients’ file and institutional
database included the following.
Demographics: age (years or months); gender; weight
(kg); height (cm). Operative details: cardiopulmonary
bypass duration (minutes); ECMO positioning in the
operating room or intensive care unit; heparin and biva-
lirudin dose; ECMO duration (hours).
Standard coagulation profile: ACT (seconds); aPTT
(seconds); International Normalized Ratio; platelet count
(cells/μl); fibrinogen (mg/dl); D-dimers (μg/l); AT
activity (%). All parameters except the ACT were mea-
sured and recorded at time 0 (T0, onset of heparin or
bivalirudin infusion), and subsequently every 12 hours
(T12, T24, T36, T48, T60, T72, T84, T96) during the
first 4 ECMO days. The ACT was measured at bedside
every 4 hours. Additional platelet count assays may be
performed in severely bleeding patients. Data after the
fourth ECMO day were available only for 50% of the
patients and were not considered for the purposes of
the present study.
Thromboelastography profile: r time (minutes); k time
(minutes); a angle (degrees); maximal amplitude (milli-
meters). All parameters were measured and recorded at
the same times as previously defined.
Bleeding and transfusions: bleeding (ml) was measured
as chest drain output, and was standardized for body
weight (ml/kg). The measurement was settled at 12
hours (from T0 through T12), 24 hours (from T12
through T24), 36 hours (from T24 through T36), and
48 hours (from T36 through T48). Total bleeding during
the first 48 hours on ECMO was measured and
expressed as milliliters per kilogram per day.
Transfusions of packed red cells, fresh frozen plasma,
and platelet concentrates were standardized (ml/kg), and
were measured at 12, 24, 36, and 48 hours (same time
intervals as above). Total transfusions for each blood
product during the whole ECMO time were measured
and expressed as milliliters per kilogram per day. Total
purified AT supplementation during the whole ECMO
time was measured and expressed as international units
per kilogram per day.
Outcome measurements: thromboembolic events; gen-
eral outcome (weaned; survived at discharge; dead dur-
ing ECMO; dead after weaning).
Cost analysis: a cost analysis was performed and
expressed in terms of daily cost (€). The items concurring
to the cost evaluation were: bivalirudin versus heparin
cost; allogeneic blood product cost; and purified AT cost.
Statistical analysis
Categorical variables are expressed as number and per-
centage. Continuous variables were checked for normal
distribution with a Kolgomorov-Smirnov test. When
normality of distribution was confirmed, they were
expressed as mean with standard deviation (text and
tables) or standard error (figures) of the mean. Other-
wise, they are expressed as median with interquartile
range.
Time-related variables were tested for between-group
and within-group differences with an analysis of var-
iance for repeated measures. Categorical variables were
tested using a Pearson’s c
2; additional tests included the
Student’s t test and the Mann-Whitney U test when
appropriate.
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The individual details of the 21 patients constituting the
s t u d yp o p u l a t i o na r es h o w ni nT a b l e1 .T e np a t i e n t s
(48%) were pediatric cases. Nine patients (43%) died
while on ECMO; seven patients (33%) were weaned
from ECMO but subsequently died; and five patients
(24%) survived at discharge.
In the H-group, one patient died on ECMO due to
intractable bleeding; in this patient, recombinant acti-
vated factor VII was used without success. One patient
suffered severe bleeding, chronic organ hypoperfusion,
and multiorgan failure; one patient had a suspicion of
cerebral thromboembolism; and one patient required a
change of the centrifugal pump due to thrombi forma-
tion inside the pump head (two thromboembolic
events).
In the B-group, two patients died on ECMO after 10
days (the longer time in our series) due to multiorgan
failure, and one patient died due to septic shock. One
patient received ECMO after being operated on for an
acute ascending aorta dissection; he reached the hospital
without consciousness, and was operated on under
emergency conditions without a neurologic assessment.
On day 2 on ECMO, an electroencephalographic control
revealed no cerebral activity, and the ECMO treatment
was stopped. One patient required an uneventful change
of the centrifugal pump after 6 days on ECMO due to
thrombi formation inside the pump head (one throm-
boembolic event). No patient in the B-group required
hemofiltration to clear excessive doses of bivalirudin.
The seven patients who died in both groups after
weaning from ECMO suffered a number of complica-
tions, including ongoing circulatory failure, sepsis, and
multiorgan failure.
The details of the patient population in the two
groups are shown in Table 2. Patients in the B-group
were significantly older and had a significantly longer
ECMO duration. They demonstrated a significantly
lower blood loss, with lower requirements of fresh fro-
zen plasma, platelet concentrates, and purified AT.
Packed red cell transfusions were not significantly (P =
0.067) reduced in the B-group.
The cost analysis was split between adults and pedia-
tric patients. There was a trend towards a minor cost in
adults, and a significantly lower cost in pediatric patients
in the B-group.
Details of the time-related blood loss and transfusional
needs are shown in Figures 1 and 2. Platelet concentrate
transfusions were significantly lower at every time inter-
val in the first 36 hours and during the whole ECMO
period.
Coagulation parameters (Figures 3 and 4) showed sig-
nificant between-group differences for the ACT (P =
0.015), aPTT (P = 0.031), and thromboelastography r
Table 1 Details of the study population (21 cases of postcardiotomy extracorporeal membrane oxygenation)
Case Age Weight
(kg)
ECMO implant
site
CPB duration
(minutes)
ECMO duration
(hours)
Thrombotic
complications
Anticoagulant Outcome
1 Adult 105 OR 498 50 None Heparin Dead on ECMO
2 Adult 66 OR 322 170 None Heparin Dead on ECMO
3 Adult 100 OR 118 40 None Heparin Survived
4 Infant 2.9 OR 115 124 None Heparin Dead on ECMO
5 Child 15 OR 74 40 None Heparin Survived
6 Infant 3.6 ICU 125 110 None Heparin Weaned and dead
7 Newborn 2.7 OR 273 90 None Heparin Dead on ECMO
8 Newborn 3 ICU 317 16 None Heparin Dead on ECMO
9 Child 45 ICU 150 234 None Bivalirudin Dead on ECMO
10 Adult 60 ICU 73 88 None Bivalirudin Weaned and dead
11 Adult 74 OR 221 135 None Bivalirudin Survived
12 Adult 95 OR 180 39 None Bivalirudin Dead on ECMO
13 Adult 76 ICU 345 262 None Bivalirudin Weaned and dead
14 Adult 85 OR 198 233 None Bivalirudin Dead on ECMO
15 Adult 65 OR 442 69 None Bivalirudin Survived
16 Adult 75 OR 402 190 None Bivalirudin Weaned and dead
17 Adult 65 OR 315 67 None Bivalirudin Weaned and dead
18 Infant 7 ICU 85 175 None Bivalirudin Weaned and dead
19 Newborn 3.3 OR 255 110 None Bivalirudin Survived
20 Infant 7.6 OR 266 168 Yes Bivalirudin Weaned and dead
21 Newborn 2.6 OR 559 87 None Bivalirudin Dead on ECMO
CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenation; OR, operating room.
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Parameter H-group (n = 8) B-group (n = 13) P value
Age (years) 13.9 ± 19 36.5 ± 29 0.045
Pediatric patients 5 (62%) 4 (31%) 0.154
Weight (kg) 37 ± 45 51 ± 34 0.446
Time on cardiopulmonary bypass (minutes) 230 ± 146 269 ± 142 0.562
ECMO positioning in the operating room 6 (75%) 9 (69%) 0.772
Time on ECMO (hours) 80 ± 52 143 ± 73 0.036
Use of intra-aortic balloon pump 1 (12%) 5 (38%) 0.336
Total bleeding (ml/kg/day)° 51 ± 46 16 ± 13 0.015
Total packed red cells (ml/kg/day) 25 (51) 15 (20) 0.067
Total fresh frozen plasma (ml/kg/day) 12 (76) 5.9 (9) 0.020
Total platelets (ml/kg/day) 33 (53) 3 (7) 0.008
Total purified antithrombin (IU/kg/day) 13 (31) 7 (13) 0.048
Cost in adults (€/day) 3,313 ± 2,818 1,807 ± 886 0.165
Cost in children (€/day) 760 ± 237 312 ± 56 0.008
Data presented as mean ± standard deviation, number (%) or median (interquartile range). ECMO, extracorporeal membrane oxygenation. ° during the first 48
hours
P= 0.015
Figure 1 Time-related blood loss. Bleeding rate at 12-hour intervals (ml/kg) and total bleeding during the first 48 hours (ml/kg/day) on
extracorporeal membrane oxygenation (ECMO). Data expressed as mean with standard error of the mean.
Ranucci et al. Critical Care 2011, 15:R275
http://ccforum.com/content/15/6/R275
Page 5 of 11time (P = 0.05) at the analysis of variance for repeated
measures. The ACT was significantly longer in the B-
group from T48 through T84; the aPTT was signifi-
cantly longer at T12, T24, T36, T72, T84, and T96. The
r time was significantly longer at T60 and T72 in the B-
group, always being above the upper normal limit;
whereas in the H-group, the value fell into the normal
range at T60 and T72. The other thromboelastography-
derived parameters (k time, a angle, and maximal ampli-
tude ) did not differ between groups at any point in
time. The platelet count did not significantly differ
between groups at any point in time; notably, this was
obtained using a significantly higher dose of platelet
concentrates in the H-group. The nadir platelet count
during the ECMO procedure was significantly (P =
0.022) lower in the H-group (30,600 ± 12,500 cells/μl)
than in the B-group (46,900 ± 17,400 cells/μl).
The International Normalized Ratio, fibrinogen, and
D-dimer levels did not differ between groups at any
point in time. AT activity was similar in the two groups;
however, to maintain the AT activity value, a signifi-
cantly higher amount of purified AT was administered
in the H-group.
The dose regimen of heparin and bivalirudin at differ-
ent points in time is shown in Figure 5. There was a
trend towards a time-dependent dose increase for
heparin, with doses ranging from 2 to 10 IU/kg/hour;
the bivalirudin dose ranged between 0.05 and 0.1 mg/
kg/hour.
Discussion
Anticoagulation for postcardiotomy ECMO is still a
challenging issue. In the majority of cases, ECMO is
established intraoperatively or in the first postoperative
hours to support failing circulation in the case of acute
heart failure. Under these circumstances, the hemostatic
system of the patient is affected by the effects of cardio-
pulmonary bypass and of the operation itself. When
ECMO is implanted intraoperatively, the patient has
usually been already under cardiopulmonary bypass for
Heparin group   Bivalirudin group
P<0.05
P<0.05
P<0.05
P<0.05
P<0.01
Figure 2 Transfusional needs. Allogeneic blood products used during the first 48 hours on extracorporeal membrane oxygenation (ECMO) (ml/
kg) and during the whole ECMO duration (ml/kg/day). Data expressed as median with interquartile range. FFP, fresh frozen plasma; PLT, platelet
concentrates. PRC, packed red cells.
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due to the repeated weaning attempts. As a result, the
platelet count is severely decreased, the platelet function
impaired, and both coagulation factors and natural
anticoagulants (AT) are consumed. Under these condi-
tions, the patient is particularly prone to severe bleed-
ing, and actually bleeding has been reported as the
major life-threatening complication in the first hours
after ECMO implantation [6,7].
Heparin has been the classical anticoagulant since the
very beginning of the ECMO experiences. It is not the
ideal anticoagulant for this procedure, however, for a
number of reasons. Heparin is not a direct thrombin inhi-
bitor: it requires AT to correctly antagonize thrombin, and
is ineffective in blocking the clot-bound thrombin [12]. At
the onset of ECMO, and throughout the whole procedure,
AT values are low, and correction of low AT levels with
purified AT leads to a fluctuation of the AT levels that
leads to a variable pattern of heparin responsiveness,
requiring several adjustments of the heparin dose [13].
Moreover, heparin is bound by the endothelial surface,
bound by circulating blood cells, and avidly sequestered
by platelets [13]. Again, the platelet count during the
ECMO procedure is generally low and variable due to
platelet concentrate administration. This pattern adds
variability to the efficacy of heparin in blocking throm-
bin and achieving a correct anticoagulation.
Heparin itself is responsible for thrombocytopenia
through nonimmune-mediated as well as immune-
mediated mechanisms. HIT is quite common during
ECMO procedures [9,10] and may determine an addi-
tional burden for the ECMO patient. For this reason,
alternative anticoagulation strategies have been advo-
cated by some authors [9,14].
Bivalirudin is a direct thrombin inhibitor, currently
approved for anticoagulation during percutaneous cor-
onary interventions and acute coronary syndrome. It has
a short half-life of about 25 minutes and is partially
cleaved by the kidney [15,16]. Bivalirudin has been safely
used for cardiopulmonary bypass during cardiac
P= 0.026
P= 0.051
P= 0.001
P= 0.008
P= 0.032
P= 0.004
P= 0.03
P= 0.001
P= 0.001
P= 0.016
Normal range
P= 0.05
P= 0.019
Figure 3 Coagulation parameters. Activated clotting time (ACT), activated partial thromboplastin time (aPTT), reaction (R) time at
thromboelastography, and platelet count during the first 96 hours on extracorporeal membrane oxygenation. Data expressed as mean with
standard error of the mean.
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ever, due to its cost, the lack of an antidote, and difficult
monitoring with standard ACT it is not routinely used
for operative cardiopulmonary bypass.
The use of bivalirudin for ECMO procedures remains
anedoctical and limited to cases of overt acute HIT dur-
ing the procedure [18-20]. There is no well-established
protocol for bivalirudin use in postcardiotomy ECMO
patients. Koster and colleagues and Pappalardo and col-
leagues used a small bolus (0.5 mg/kg) followed by an
infusion (0.05 to 0.15 mg/kg/hour) [19,20]. In our series,
we did not use any bolus, considering the risk for severe
bleeding. Even if this approach resulted in a satisfactory
achievement of the target anticoagulation, further stu-
dies are required to assess whether a bolus dose is
required.
To our knowledge, the present study is the only com-
parative study of heparin versus bivalirudin anticoagula-
tion for ECMO patients. The main results of our study
are as follows. First, patients in the B-group had a more
stable anticoagulation profile, with significantly longer
ACT and aPTT values maintained within the required
range. Second, the platelet count and AT levels were
better preserved in the B-group. Although no significant
between-group differences were found for both of these
variables, this was the effect of a significantly larger use
of platelet concentrates and purified AT in the H-group.
Third, bleeding during the ECMO period was signifi-
cantly lower in the B-group, with a significantly lower
need for fresh frozen plasma and platelet concentrate
transfusions. Packed red cell transfusions were reduced
i nt h eB - g r o u p ,b u tt h er e l a t i v e l yl o ws a m p l es i z ed i d
not allow one to reach a significant between-group dif-
ference. Fourth, costs were significantly reduced in the
B-group for pediatric patients. These costs were 50%
reduced in adult patients, but again due to the limited
sample size, without reaching a significant between-
group difference. Finally, the rate of thromboembolic
events was not significantly different between the two
groups.
Figure 4 Coagulation parameters. International Normalized Ratio (INR), fibrinogen, D-dimers, and antithrombin activity during the first 96 hours
on extracorporeal membrane oxygenation. Data expressed as mean with standard error of the mean. OK.
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(H-group) were suffering from more bleeding and a lar-
ger need for transfusions may seem contradictory. How-
ever, inadequate thrombin suppression by heparin may
generate intravascular and extravascular thrombus gen-
eration, with coagulation factors and platelet consump-
tion, creating a condition of consumption coagulopathy.
It is possible that using larger doses of heparin may
result in a better control of bleeding.
Our study suggests that bivalirudin-based anticoagula-
tion for ECMO patients is safe, effective, and limits the
costs involved in an ECMO procedure. From an inter-
pretative point of view, the starting point is that bivalir-
udin preserved the platelet count and AT activity better
than heparin. We can hypothesize that this may be due
to the absence of heparin-mediated platelet consump-
tion and to the direct thrombin inhibition exerted by
bivalirudin. The AT cofactor is not required for bivaliru-
din-mediated thrombin inhibition, and consequently the
AT activity is better preserved. Even in the B-group,
however, additional doses of purified AT were required
to maintain the AT value within the normal range. This
may be due to an incomplete thrombin inhibition, to a
defect in hepatic AT synthesis, and to the presence of
an endothelial dysfunction with release of endothelial
heparinoids.
Probably as a consequence of the preservation of pla-
telet count, bleeding was significantly contained in the
B-group, therefore limiting the need for administration
of allogeneic blood products. In our series, we could not
diagnose any HIT event. Routine search for heparin-PF4
antibodies only recently entered into our clinical prac-
tice, however, and we cannot therefore exclude that
some patients may have developed antibodies.
There are some limitations to our study. First, this is a
retrospective study and therefore only generates the
hypothesis that a bivalirudin-based anticoagulation for
ECMO patients is superior to the classical heparin-
based anticoagulation. The patient population is limited
and heterogeneous for age. However, planning a rando-
mized controlled trial in this setting of patients is hard
to hypothesize. The limited amount of postcardiotomy
ECMO performed in cardiac surgery institutions makes
a single-center randomized trial impossible; multicenter
Figure 5 Dose regimen of heparin and bivalirudin at different time points. Bivalirudin and heparin dose during the first 96 hours on
extracorporeal membrane oxygenation. Data expressed as mean with standard error of the mean. OK.
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specific for a postcardiotomy ECMO implantation make
it difficult to settle a randomization process and to col-
lect an informed consent from the relatives of the
patient. However, further studies aimed to determine
the correct bivalirudin dose for ECMO treatments and
to confirm its safety and efficacy are warranted.
A second limitation of our study is that we are lacking
data on platelet function during bivalirudin-based versus
heparin-based anticoagulation, and we are also lacking
important information regarding thrombin generation.
Thrombin generation tests should be included in future
studies to highlight the differences between the two
protocols.
As a third limitation, we recognize that differences in
ECMO systems may introduce a bias in the results -
namely, the use of phosphorylcholine-coated (Sorin sys-
tem) versus heparin-coated (Maquet system) surfaces
may change the platelet count. Only one patient in the
B-group received the Maquet system, however, and we
therefore cannot compare subgroups based on the
ECMO system used.
Conclusions
Our study suggests that bivalirudin may be safely and
effectively used in postcardiotomy ECMO to limit bleed-
ing and allogeneic blood product transfusions. The lim-
ited size of our patient population and the limitations of
our study do not allow us to claim a superiority of biva-
lirudin versus heparin for postcardiotomy ECMO.
Our results may be tested for other clinical situations
where the ECMO is used, such as venovenous respira-
tory support in cases of acute lung failure recently used
widely for the treatment of the H1N1 pandemic.
Key messages
￿ Bivalirudin can be safely used in a heparin-free
protocol for anticoagulation in postoperative ECMO
patients.
￿ Patients treated with bivalirudin had a lower blood
loss than patients treated with heparin, and required
less fresh frozen plasma, platelet concentrates, and
antithrombin supplementation during the ECMO
period.
￿ In the subset of pediatric patients, significant cost
containment was achieved.
￿ No differences in thromboembolic complications
where observed in bivalirudin-treated versus
heparin-treated patients.
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